FASENRA
As listed in the register: FASENRA 30 mg, solution injectable en seringue préremplie
30 mg · solution injectable
- Prescription only
- Active substance
- Benralizumab
- Made by
- ASTRAZENECA AB
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
Mediclarum has not yet retrieved and stored the official label for this product, so none of its text is shown here. Open the official leaflet
How it works
From the US prescribing label for the same active substance (FASENRA). It describes the substance, not this exact product.
Benralizumab is a humanized afucosylated, monoclonal antibody (IgG1, kappa) that directly binds to the alpha subunit of the human interleukin-5 receptor (IL-5Rα) with a dissociation constant of 11 pM.
The IL-5 receptor is expressed on the surface of eosinophils and basophils.
Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2026-05-13
Safety of the active substance
From the US prescribing label for the same active substance (FASENRA). It describes the substance, not this exact product.
- FASENRA is contraindicated in patients who have known hypersensitivity to benralizumab or any of its excipients [see Warnings and Precautions (5.1) ].
- Known hypersensitivity to benralizumab or excipients.
Most common adverse reactions (incidence greater than or equal to 5%):.
Quoted from the US prescribing label for the same active substance. Your own pack’s leaflet is the authority for your product. DailyMed
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
European UnionNo exact match for this strength and form
Spain2 matching products
CanadaNo exact match for this strength and form
Netherlands1 matching products
Details
| Made by | ASTRAZENECA AB |
|---|---|
| Active substance | Benralizumab |
| Strength | 30 mg |
| Form | solution injectable |
| Route | sous-cutanée |
| Dispensing (as stated by the register) | prescription réservée aux spécialistes et services NEUROLOGIE · prescription réservée aux spécialistes et services PEDIATRIE · prescription réservée aux spécialistes et services MEDECINE INTERNE · prescription réservée aux spécialistes et services HEMATOLOGIE · prescription réservée aux spécialistes et services NEPHROLOGIE · prescription réservée aux spécialistes et services PNEUMOLOGIE · prescription réservée aux spécialistes et services RHUMATOLOGIE · prescription réservée aux spécialistes et services DERMATOLOGIE · liste I · prescription réservée aux spécialistes et services OTO-RHINO-LARYNGOLOGIE · prescription réservée aux spécialistes et services ALLERGOLOGIE |
| Marketed | Yes, according to the register |
| Authorisation procedure | Procédure centralisée |
| EU number | EU/1/17/1252 |
| Name in the register | FASENRA 30 mg, solution injectable en seringue préremplie |
| Packs | 1 seringue préremplie en verre de 1 ml avec une aiguille et un protège -aiguille rigide et un bouchon-piston |
| CIS | 63562134 |
| CIP13 | 3400930132944 |
Source: Base de données publique des médicaments · 2026-09-30 · not reviewed by a clinician
Source : Base de données publique des médicaments (ANSM / Ministère de la Santé), sous Licence Ouverte. Reuse terms: Licence Ouverte / Open Licence (Etalab).
Other strengths and forms
2 products are sold under this name. Grouped by form; a number on a strength means several companies make it.
- solution injectable2 products
30 mg2
30 mg · 2 companies
- ASTRAZENECA AB · this page
- ASTRAZENECA AB
Same active substance
These contain the same substance. That does not mean one can replace another — ask a pharmacist.